CJC-1295 (No DAC) 10 mg

CJC-1295 (No DAC) for research: identity and specifications

CJC-1295 without DAC (modified GRF 1-29, also called Mod GRF 1-29) is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) carrying four amino acid substitutions relative to native GRF 1-29 (D-Ala at position 2, Gln8, Ala15 and Leu27) (CAS 863288-34-0). Supplied as a 10 mg vial, lyophilized powder, with no fillers, carriers or excipients, at ≥98% purity by HPLC and the lot-specific value reported on the certificate of analysis.

Scientific background

The substitutions are designed to increase resistance to enzymatic cleavage compared with native GRF 1-29, so the peptide is used in experimental models to study binding to the GHRH receptor on pituitary somatotroph cells and the downstream cAMP signaling that follows receptor activation. The variant has no drug affinity complex (DAC) and therefore no albumin-binding domain.

Preclinical literature uses it in comparative stability studies against native GRF 1-29 and in cell and rodent models of the hypothalamic-pituitary somatotropic axis, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• GHRH receptor binding in pituitary cell models
• Downstream cAMP signaling
• Enzymatic stability compared with native GRF 1-29
• Pulsatile secretagogue signaling in experimental models of the somatotropic axis

Technical specifications

Analytical quality and chain of custody

Every lot of CJC-1295 (No DAC) is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) for each lot can be reviewed before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the CJC-1295 (No DAC) supplied?

≥98% by HPLC, with the lot-specific value reported on the certificate of analysis (COA).

What is the difference between CJC-1295 with and without DAC?

The variant without DAC has no drug affinity complex and therefore lacks the albumin-binding domain of the DAC version, giving it a different profile in experimental models. This product is the no-DAC peptide (modified GRF 1-29, PubChem CID 56841945).

How should the compound be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Does the certificate of analysis come with the lot?

Yes, every lot has a matching COA that can be verified before purchase using the button on this page.

Who can purchase CJC-1295 (No DAC)?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA, and the molecular structure in the PubChem database.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.